BioLineRx (BLRX) Capital Expenditures Growth (1y) (2014 - 2024)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 227.76% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 0.57% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 143.40% |
| 10 | BioLineRx | 9.32 Bn | 9.30 Bn | 154,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 137.50% |
| Jun 30, 2024 | 59.70% |
| Mar 31, 2024 | 0.00% |
| Dec 31, 2023 | 71.93% |
| Sep 30, 2023 | 91.67% |
| Jun 30, 2023 | -52.27% |
| Mar 31, 2023 | -77.78% |
| Dec 31, 2022 | 8.06% |
| Sep 30, 2022 | -500.00% |
| Jun 30, 2022 | -131.58% |
| Mar 31, 2022 | 5.26% |
| Dec 31, 2021 | -6,300.00% |
| Dec 31, 2020 | 107.69% |
| Dec 31, 2019 | 86.60% |
| Jun 30, 2019 | 0.00% |
| Mar 31, 2019 | 42.59% |
| Dec 31, 2018 | 57.64% |
| Jun 30, 2018 | 51.11% |
| Mar 31, 2018 | -20.00% |
| Dec 31, 2017 | -304.46% |
| Jun 30, 2017 | -66.67% |
| Mar 31, 2017 | 67.15% |
| Dec 31, 2016 | 151.61% |
| Jun 30, 2016 | 98.12% |
| Mar 31, 2016 | 8.05% |
| Dec 31, 2015 | -600.00% |
| Sep 30, 2015 | -1,194.12% |
| Jun 30, 2015 | -3,404.88% |
| Mar 31, 2015 | -217.02% |
| Dec 31, 2014 | -3.33% |
| Sep 30, 2014 | -257.89% |
| Jun 30, 2014 | -64.00% |
| Mar 31, 2014 | -327.27% |